| BIOINVENT INTERNATIONAL AB Patent applications |
| Patent application number | Title | Published |
|---|
| 20120077710 | METHOD FOR AN IN VITRO MOLECULAR EVOLUTION OF ANTIBODY FUNCTION - The present invention relates to a method for in vivo molecular evolution of antibody function. According to the present invention, a nucleic acid encoding a CDR that is normally contained in a framework (the “original framework”), which differs from a selected master framework, is amplified from an immunoglobulin gene and is inserted into a nucleic acid encoding the selected master framework. The invention further provides an antibody library, such as a phage display library, and methods of making the same. | 03-29-2012 |
| 20100119526 | DLL4 Signaling Inhibitors and Uses Thereof - DLL4-binding antibodies, specifically antibodies preventing Notch signaling and internalization of DLL4, can: more efficiently than inhibitors only preventing DLL4-mediated Notch-signaling disrupt angiogenesis and pathological processes including tumor growth. | 05-13-2010 |
| 20090208503 | IMMUNOTHERAPEUTIC TREATMENT - The use of immunotherapy against oxidised LDL to induce regression of pre-existing atherosclerotic lesions in an individual. The immunotherapy can be passive immunotherapy utilising antibodies that bind to epitopes present on oxidised LDL, or active immunotherapy utilising a vaccine composition for induction of an immune response against epitopes present on oxidised LDL. | 08-20-2009 |
| 20090060915 | POLYPEPTIDE, VACCINE AND USE THEREOF - The present invention relates to prophylactic or therapeutic treatments for hindering blood vessel formation (for example, angiogenesis) for example for hindering tumour growth. In particular, the invention relates to a vaccine or medicament comprising a whole angiomotin molecule or a fragment thereof which may be used to generate immune responses to angiomotin. The invention also provides antibodies specific for a whole angiomotin molecule or a fragment thereof for use in prophylactic or therapeutic treatments. | 03-05-2009 |
